REFERENCES
- Braden, M.R.; Parrish, J.C.; Naylor, J.C. & Nichols, D.E. 2006. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology 70 (6): 1956–64.
- Caldicott, D.G.E.; Bright, S.J. & Barratt, M.J. 2013. NBOMe: A very different kettle of fish. The Medical Journal of Australia 199 (5): 322–23.
- Erowid, E. & Erowid, F. 2013. Spotlight on NBOMes: Potent psychedelic issues. Available at: http://www.erowid.org/chemicals/nbome/nbome_article1.shtml.
- Halberstadt, A.L. & Geyer, M.A. 2014. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77 (February): 200–207.
- Hill, S.L.; Doris, T.; Gurung, S.; Katebe, S.; Lomas, A.; Dunn, M.; Blain P. & Thomas, S.H.L. 2013. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: Case series. Clinical Toxicology 51 (6): 487–92.
- Lawn, W.; Barratt, M.; Williams, M.; Horne, A. & Winstock, A. 2014. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.” Journal of Psychopharmacology 28 (8): 780–788.
- Ninnemann, A. & Stuart, G.L. 2013. The NBOMe series: A novel, dangerous group of hallucinogenic drugs. Journal of Studies on Alcohol and Drugs 74 (6): 977–78.
- Passie, T.; Halpern, J.H.; Stichtenoth, D.O.; Emrich, H.M. & Hintzen, A. 2008. The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics 14 (4): 295–314.
- Poklis, J.L.; Charles, J.; Wolf, C.E. & Poklis, A. 2013. High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomedical Chromatography: BMC 27 (12): 1794–1800.
- Poklis, J.L.; Devers, K.G.; Arbefeville, E.F.; Pearson, J.M.; Houston, E. & Poklis, A. 2014. Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Science International 234 (January): e14–20.
- Rose, S.R.; Poklis, J.L. & Poklis, A. 2013. A case of 25I-NBOMe (25-I) intoxication: A new potent 5-HT2A agonist designer drug. Clinical Toxicology 51 (3): 174–77.
- Stellpflug, S.J.; Kealey, S.E.; Hegarty, C.B. & Janis, G.C. 2013. 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical case with unique confirmatory testing. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology 10 (1): 45–50.
- Walterscheid, J.P.; Phillips, G.T.; Lopez, A.E.; Gonsoulin, M.L.; Chen, H.-H. & Sanchez, L.A. 2014. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. The American Journal of Forensic Medicine and Pathology 35 (1): 20–25.
- Zuba, D.; Sekuła, K. & Buczek, A. 2013. 25C-NBOMe: New potent hallucinogenic substance identified on the drug market. Forensic Science International 227 (1–3): 7–14.